STAT-Diagnostica specializes in the development of Point of Care diagnostic systems to facilitate the diagnosis of diseases that require fast and accurate results.
Kurma Life Sciences Partners has led this round with the participation of existing shareholders Ysios Capital -which led the first round in 2011- and Axis, together with Idinvest, Boehringer Ingelheim Venture Fund and Caixa Capital Risc, the venture capital manager of "la Caixa".

STAT-Diagnostica, a company specialized in the development of Point of Care diagnostic systems, announced today the closing of a Series B financing round, for a total amount of 17 million euros, which will finance the industrialization process of its diagnostic system and the clinical validation of the first products. This capital increase was led by Kurma Life Sciences Partners, with the participation of Idinvest Funds, Boehringer Ingelheim Venture Fund and Caixa Capital Risc, the venture capital manager of "la Caixa", as well as the existing investors Ysios Capital, which becomes the main shareholder, and Axis. With this transaction, STAT Diagnostica closes the largest financing round of a Spanish company in the biotechnology and medical technology sector in recent years.

STAT-Diagnostica, founded in 2010 and headquartered in the Barcelona Science Park, develops a novel Point of Care diagnostic system that simplifies processes and reduces the time required to obtain results in certain clinical analyses. This diagnostic system is a versatile, easy-to-use platform that consolidates molecular diagnostic and immunoassay capabilities in a single system. Its main applications are aimed at the detection of infectious diseases, the determination of antibiotic resistance and the measurement of biomarkers in patients in critical states or in emergency situations.

STAT's platform enables not only multi-analyte and multi-sample detection capability but also a significant reduction of current diagnostic times, in some cases from several days to 1 hour or even 15 minutes. The speed in obtaining results will make it easier for the physician to apply the most appropriate treatment from the very first moment, which will be of clear benefit to the patient in addition to direct and indirect savings in healthcare costs.
"The financial support received will provide the company with the necessary resources to reach the European market in 2015. Closing this round of financing endorses the work of the entire STAT-Diagnostica team and confirms the commercial interest in our technology within the molecular diagnostics and high sensitivity immunoassay markets," says Jordi Carrera, CEO and Co-Founder of STAT Diagnostica.

"STAT-Diagnostica has great potential both from the technological point of view of its diagnostic platform and the products it plans to develop. It also has a human team that has demonstrated high training, quality and professionalism. We are very pleased to have led this financing round and to share with the rest of the investors the vision of making STAT-Diagnostica a clear reference in Point of Care diagnostics in the coming years", says Rémi Droller, Managing Partner of Kurma Life Scienes Partners.

Raul Martin-Ruiz, Investment Director at Ysios Capital, adds, "When we first invested in STAT Diagnostica in June 2011 it was little more than an idea. In less than two years the company has gone from being an idea to having pre-industrial validation of the technology and has also been able to attract specialized international investors who confirm its potential and differentiation. We have reinforced our commitment to STAT, having invested again in this round, in whose configuration we have played an essential role. We are very pleased that a Spanish company in our portfolio has been able to attract investors of international prestige and close a financing round of 17 million euros in the current context. It is, without a doubt, excellent news that brings visibility and credibility to the sector."

Grant Thornton and Cuatrecasas Gonçalves Pereira have acted respectively as financial and legal advisor to the new investors, and Rousaud Costas Duran as legal advisor to the company.